Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study.
- DOI
- 10.1177/17588359251386611
- Published
- 2025
- Container
- Therapeutic advances in medical oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1177/17588359251386611,
title = {Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study.},
author = {Skoulidis F and Borghaei H and Garon EB and Leal TA and Kaufman J and Liu SV and Nadler E and Patel SP and Peters S and Ricciuti B and Gautam A and Emeribe U and Luciani-Silverman L and Heymach JV},
year = {2025},
journal = {Therapeutic advances in medical oncology},
doi = {10.1177/17588359251386611},
url = {https://doi.org/10.1177/17588359251386611}
}RIS
TY - JOUR TI - Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study. AU - Skoulidis F AU - Borghaei H AU - Garon EB AU - Leal TA AU - Kaufman J AU - Liu SV AU - Nadler E AU - Patel SP AU - Peters S AU - Ricciuti B AU - Gautam A AU - Emeribe U AU - Luciani-Silverman L AU - Heymach JV PY - 2025 JO - Therapeutic advances in medical oncology DO - 10.1177/17588359251386611 UR - https://doi.org/10.1177/17588359251386611 ER -
APA
F, S., H, B., EB, G., TA, L., J, K., SV, L., E, N., SP, P., S, P., B, R., A, G., U, E., L, L., & JV, H. (2025). Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study.. Therapeutic advances in medical oncology. https://doi.org/10.1177/17588359251386611
Source records
- pubmed · retrieved 2026-09-26T21:21:31.139Z